BioCorp and Diabeloop announced today that they have entered into a collaboration agreement to develop new personalized diabetes treatments.
Diabeloop develops automated insulin delivery systems (AID), including a self-learning algorithm, hosted in a handset and connected to a continuous glucose monitoring system (CGM) and an insulin pump. The platform analyzes glucose data, calculates the correct dose of insulin for administration and manages it automatically.
BioCorp is developing Mallya, an intelligent sensor for insulin injection pens that is CE-marked in Europe. The platform is compatible with any single-use insulin pen and enables reliable monitoring of the doses selected for injection. It also offers patients with diabetes better compliance with their treatment.
You can find the full story on our sister site Drug Delivery Business News.
